Medical Program: Combination to Combat: Second Line Therapy Options for NSCLC

Combination to Combat: Second Line Therapy Options for NSCLC

Combination to Combat: Second Line Therapy Options for NSCLC
RestartResume
In an evolving therapeutic landscape, chemoimmunotherapy is becoming the standard of care. But could we be leaving our patients with fewer options?
  • Overview

    Chemoimmunotherapy has become more prevalent as a first-line treatment option for patients with non-small cell lung cancer (NSCLC). However, by compressing two therapies into one, we could be left with fewer alternatives if patients progress. Dr. Howard Jack West exposes these potential challenges and offers his perspective on second-line approaches in NSCLC care.

    Closing the Gaps in NSCLC is sponsored by Lilly. Content for this non-certified educational series is produced and controlled by ReachMD. This series is intended for health care professionals only.

Facebook Comments

Sign up for the Global Oncology Academy newsletters.
Comprehensive Oncology Education.

Better education for a better you.

* Required
Optional

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free